GT Biopharma (GTBP)
(Delayed Data from NSDQ)
$2.18 USD
0.00 (-0.01%)
Updated Sep 13, 2024 02:39 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GTBP 2.18 0.00(-0.01%)
Will GTBP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GTBP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GTBP
GT Biopharma, Inc. (GTBP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now
GTBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy
Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?
Other News for GTBP
GT Biopharma GAAP EPS of -$2.17
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GTBP Stock Earnings: GT Biopharma Reported Results for Q2 2024
One new option listing and eighteen option delistings on July 22nd
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia